Health · Medical Research · 5 hrs ago
Hackensack Meridian offers brain cancer imaging drug in the Northeast
Hackensack Meridian Health is offering Pixclara, a drug used in PET imaging to help assess brain cancer.
The Edison, New Jersey-based health system is offering it at Hackensack Meridian Hoboken Imaging Services in Hoboken.
Pixclara is FDA-approved for this imaging use.
The health system says it is the first hospital network in the Northeast to administer the drug.
PET imaging can help clinicians assess brain cancer, but Pixclara is an imaging drug, not a treatment.
The service is now being offered at the Hoboken location.
Hackensack Meridian Health has become the first hospital network in the Northeast U.S. to administer Pixclara.
Pixclara is an FDA-approved PET imaging drug used to help assess brain cancer.
The health system is offering the drug at Hackensack Meridian Hoboken Imaging Services in Hoboken, New Jersey.
The announcement was reported in an Oct. 30 news release.
- Who
- Hackensack Meridian Health.
- What
- It is offering Pixclara, an FDA-approved PET imaging drug used to help assess brain cancer.
- When
- The news release was dated Oct. 30.
- Where
- Hackensack Meridian Hoboken Imaging Services in Hoboken, New Jersey.
- Why
- The drug is used to help assess brain cancer.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Health system
- Hackensack Meridian Health
- Regional first
- First hospital network in the Northeast U.S. to administer Pixclara
- Drug
- Pixclara
- Purpose
- PET imaging drug used to help assess brain cancer
- Location
- Hackensack Meridian Hoboken Imaging Services, Hoboken, New Jersey
- Release date
- Oct. 30